General Writings on Brain, Mind and Language

A comprehensive archive on neurology, trauma, behaviour, and the human experience.

Explore the medical cannabis collection — 26 articles on evidence, clinical uses, safety and unusual case reports.

Explore psilocybin and psychedelic therapy — thirty articles organised into clinical applications, addiction, and safety and treatment practice.

Trauma & Interpersonal Harm

Essays that look closely at the dynamics of harm and how recovery is often misunderstood.

Trauma

Sexual Health, Body & Identity

Articles on how our bodies and identities become medicalised or moralised.

Body Image

Alcohol, Addiction & Behaviour

Examining alcohol use and how labels shape identity and social attitudes.

Alcoholism

Mood, Depression & Communication

How interaction and inner imagery can relieve or worsen distress.

Emotions

Complex Presentations & Controversial Diagnoses

Where psychiatry, belief, and suggestion collide.

Diagnosis

Medical Cannabis: Evidence, Uses and Case Reports

A collection of 26 articles on cannabinoid medicines, clinical uses and unusual case reports, with evidence summaries, credited public-domain images and links to original research and clinical guidance.

Start here: How to read the evidence, then choose a clinical topic below. Case reports generate questions; they do not establish that a treatment works for everyone.

Understand the evidence

Clinical uses and their limits

Further evidence and unresolved questions

Focused reviews of mixed results, negative findings and the questions that remain open.

Case reports: unusual benefits and harms

Collection expanded 11 October 2026. These articles provide educational information and do not replace individual clinical assessment.

Psilocybin and Psychedelic Therapy

Thirty clinical articles covering potential benefits, negative findings, safety and unresolved questions across psilocybin and related treatments.

Clinical applications

Psilocybin for Depression: Benefits, Limitations and Lasting Recovery

Psilocybin for depression: antidepressant benefits, negative findings, comparison with escitalopram, relapse, safety and the meaning of recovery.

Ketamine and Esketamine for Depression: Benefits, Maintenance Treatment and Clinical Limits

Ketamine and esketamine for depression: comparative benefits, negative findings, relapse prevention, psychotherapy, monitoring and UK and US access.

DMT for Depression: Rapid Effects, Clinical Evidence and the Limits of a Short Experience

DMT for depression: controlled and open-label findings, treatment duration, medication review and the distinction from 5-MeO-DMT and ayahuasca.

Psilocybin for Bipolar Depression: Antidepressant Effects, Hypomania and Mood Stability

Psilocybin for bipolar II depression: early antidepressant findings, hypomania, sleep disruption, lithium interactions and long-term mood stability.

Psilocybin in Cancer and Palliative Care: Distress, Meaning and Choice

Psilocybin for cancer-related anxiety, depression and existential distress, with attention to durability, palliative care, consent and treatment burden.

LSD for Anxiety Disorders: Symptom Relief, Treatment Burden and Lasting Recovery

LSD for anxiety: published trials, 2026 sponsor-reported phase 3 findings, psychological support, long sessions, adverse effects and lasting recovery.

Psilocybin for Obsessive–Compulsive Disorder: Symptoms, Treatment and Clinical Evidence

Psilocybin for OCD: compulsions, recent clinical trials, exposure and response prevention, medication, safety and lasting functional improvement.

Psilocybin for Body Dysmorphic Disorder: Appearance Preoccupation, Symptoms and Recovery

Psilocybin for body dysmorphic disorder: preliminary clinical findings, appearance preoccupation, brain imaging, psychological care and recovery.

Psilocybin for Anorexia Nervosa: Psychological Change, Nutrition and Medical Safety

Psilocybin for anorexia nervosa: psychological symptoms, nutritional recovery, pilot findings, medical vulnerability and continuing specialist care.

Psilocybin for Migraine and Cluster Headache: Prevention, Pain and Clinical Evidence

Psilocybin for migraine and cluster headache: attack prevention, controlled trial results, negative findings, safety and established headache care.

Psilocybin for Fibromyalgia and Chronic Pain: Symptoms, Function and Treatment Limits

Psilocybin for fibromyalgia and chronic pain: pain intensity, daily function, early clinical findings, phantom limb pain and continuing treatment.

Psilocybin for PTSD: Trauma Symptoms, Psychological Support and Clinical Evidence

Psilocybin for PTSD: early clinical findings, trauma symptoms, psychological support, memory, safety and the separate evidence for MDMA therapy.

MDMA-Assisted Therapy for PTSD: Clinical Benefits, Safety and Continuing Care

MDMA-assisted therapy for PTSD: controlled outcomes, expectation, cardiovascular safety, consent, professional boundaries and continuing trauma care.

Psilocybin in Parkinson’s Disease: Depression, Anxiety and the Limits of Motor Improvement

Psilocybin in Parkinson’s disease: mood symptoms, exploratory motor and cognitive findings, medication safety and the absence of proven disease modification.

Psilocybin for Healthcare Worker Depression and Burnout: Recovery and Working Conditions

Psilocybin for healthcare worker depression and burnout: controlled findings, uncertain burnout benefits, confidentiality and the need to address working conditions.

Psilocybin in HIV Care: Demoralisation, Shame and Psychological Recovery

Psilocybin in HIV care: demoralisation, HIV-related shame, trauma-related adverse effects, group therapy and the continuing importance of antiretroviral treatment.

Addiction

Psilocybin for Alcohol Use Disorder: Drinking, Relapse and Recovery

Psilocybin for alcohol use disorder: heavy drinking, negative relapse-prevention findings, psychotherapy, withdrawal and sustained recovery.

Psilocybin for Smoking Cessation: Nicotine Dependence, Abstinence and Relapse

Psilocybin for smoking cessation: nicotine dependence, randomised trial findings, sustained abstinence, relapse and established treatment options.

Psilocybin for Cocaine and Methamphetamine Use Disorders: Abstinence, Craving and Recovery

Psilocybin for cocaine and methamphetamine use disorders: a randomised cocaine trial, early methamphetamine findings, craving, safety and sustained recovery.

Psilocybin for Opioid Use Disorder: Early Evidence and the Priority of Established Care

Psilocybin for opioid use disorder: the buprenorphine pilot, mixed population findings, reward learning, overdose prevention and established treatment.

Safety and treatment practice

Psilocybin-Assisted Therapy: Clinical Uses, Mechanisms and Patient Care

A clinical account of psilocybin-assisted therapy: mechanisms, medical applications, psychological support, patient selection and continuing care.

Expectancy and Evidence in Psychedelic Therapy: Placebo Effects, Blinding and Reliable Treatment Claims

How expectancy, blinding, comparison treatments and follow-up affect psychedelic treatment claims, including negative results and unresolved questions.

Consent and Safeguarding in Psychedelic Therapy: Touch, Boundaries and Professional Accountability

Consent and safeguarding in psychedelic therapy: therapeutic touch, changing wishes, suggestibility, professional boundaries, privacy and independent accountability.

How Psilocybin Affects the Brain: Receptors, Networks and Therapeutic Change

How psilocybin affects serotonin receptors, brain networks and plasticity, and why biological changes do not by themselves establish clinical recovery.

Psilocybin and Psychedelic Therapy: Adverse Effects and Patient Safety

A clinical assessment of psychedelic safety: acute adverse effects, persistent symptoms, interactions, psychiatric vulnerability and professional care.

Difficult and Prolonged Reactions to Psychedelics: Anxiety, Dissociation and Persistent Perceptual Symptoms

Difficult and prolonged psychedelic reactions: anxiety, dissociation, HPPD, the limits of risk estimates, professional assessment and recovery.

Psilocybin and Prescribed Medicines: Antidepressants, Interactions and Withdrawal

Psilocybin and prescribed medicines: SSRIs, withdrawal, lithium, serotonin toxicity and the distinction between altered drug effects and clinical benefit.

Psychological Support in Psilocybin Therapy: Preparation, Consent and Integration

Preparation and integration in psilocybin therapy: therapeutic alliance, consent, professional boundaries, follow-up and unresolved questions about effectiveness.

Psilocybin Therapy Over Time: Durability, Relapse and Repeat Treatment

Long-term psilocybin outcomes: response, remission, one- and five-year follow-up, relapse, continuing care and the unresolved role of repeat treatment.

Psilocybin Microdosing: Mood, Cognition and the Limits of Clinical Evidence

Psilocybin microdosing: controlled findings on mood and cognition, creativity, expectation, clinical applications and unresolved long-term safety.

Body, Brain & Unusual Treatments

From seizures to microbiota, exploring the stranger corners of medicine.

FMT

Consciousness & Radical Ideas

Essays challenging conventional views of mind and experience.

Consciousness

5 1 vote
Article Rating
Subscribe
Notify of
guest
0 Comments
Oldest
Newest Most Voted
0
Would love your thoughts, please comment.x
()
x